Copy Link Print Information

Lenvatinib mesylate

(Synonyms: E7080 mesylate)
101 Cited Publications
Kundenbewertung

Based on 101 publication(s) in Google Scholar

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit: 99.91%
  • CAS. Nr.: 857890-39-2
  • Formel: C22H23ClN4O7S
  • Molecular Weight:522.96
  • Speicherung:

    4°C, sealed storage, away from moisture and light

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

  • Lenvatinib mesylate Chemical Structure
    Lenvatinib mesylate Chemical Structure
  • Experimental Validation Results for Lenvatinib mesylate
  • Experimental Validation Results for Lenvatinib mesylate
  • Experimental Validation Results for Lenvatinib mesylate
  • Experimental Validation Results for Lenvatinib mesylate
  • Experimental Validation Results for Lenvatinib mesylate
  • Experimental Validation Results for Lenvatinib mesylate
  • Experimental Validation Results for Lenvatinib mesylate
CAS. Nr.: 857890-39-2
Größe
Preis
Verfügbarkeit
Menge
Amount: USD 0.00
Please select quantity
or
or

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Lenvatinib mesylate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Finden Sie Ihren Händler vor Ort Your local distributor: Hycultec GmbHHycultec
  • Biologische Aktivität
  • Chemical Information
  • Lösungsmittel & Löslichkeit
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Lenvatinib mesylate

More
Customer Validation & Images
IHCCell Proliferation/Viability AssayRT-PCRWB
  • IHC
  • Cell Proliferation/Viability Assay
  • WB
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • WB

Alle VEGFR Isoform-spezifische Produkte anzeigen

More

Alle PDGFR Isoform-spezifische Produkte anzeigen

More
Keywords
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Einloggen
Registrieren
Sign in to MedChemExpress
Neuen Account Registrieren

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Lenvatinib mesylate Chemical Structure
    Lenvatinib mesylate Chemical Structure
    1/16
  • 1/16

    Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Transl Med. 2022 Mar 7;20(1):116. [Abstract]

    Customer Validation
     H&E examination of vehicle and Lenvatinib (10 mg/kg daily by oral gavage)-treated tumors revealed markedly increase tumor necrosis and desmoplasia in the Lenvatinib-treated samples.

  • 1/16

    Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Oncol. 2022 Oct 18;2022:4537343. [Abstract]

    Customer Validation
     HepG2 and HepG2/R cells are treated with indicated doses of Lenvatinib for 24 h, and cellular viabilities are measured.

  • 1/16

    Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Oncol. 2022 Oct 18;2022:4537343. [Abstract]

    Customer Validation
     HepG2 and HepG2/R cells are treated with or without Lenvatinib (20 μM) for 24 h, and indicated proteins are measured by western blots.

  • 1/16

    Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2021 Nov 18;7(1):359. [Abstract]

    Customer Validation
     Lenvatinib (1000 nM) has demonstrated the ability to significantly inhibit cell proliferation, and knockout of NF1 and DUSP9 significantly blocks the ability of lenvatinib to inhibit cell proliferation as well as the effect on cell number. ​

  • 1/16

    Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Jan;25(1):549-560. [Abstract]

    Customer Validation
     The cell viability is measured by CCK-8 assay at different time intervals (24, 48, 72 and 96 h) when cells are cultured with 5 μM Lenvatinib.

  • 1/16

    Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Jan;25(1):549-560. [Abstract]

    Customer Validation
     The mRNA expression of VEGFR2 in HepG2-WT/Lenvatinib (LR; 5 μM) and Huh7-WT/LR cells. VEGFR2 mRNA expression is up-regulated in HepG2-LR and Huh7LR cells.

  • 1/16

    Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Jan;25(1):549-560. [Abstract]

    Customer Validation
     The protein expression of VEGFR2 in HepG2-WT/Lenvatinib (LR; 5 μM) and Huh7-WT/LR cells. Western blotting results show the downstream target RAS/MEK/ERK axis of VEGFR2 are obviously up‐regulated in HepG2-LR and Huh7-LR cells compared with their parental cells.

  • Lenvatinib mesylate